In a clinical trial, 74% of patients with hard-to-treat, advanced sarcomas saw their disease stabilize for at least 12 weeks with manageable side effects. This lead in Phase 2 trial, would need to be followed up with successful larger trials before this combination became available to non-trial patients.
Read the full story at Northwestern Medicine.